My take on this. If it is relaxing blood vessels then maybe something like this needs to be researched if the reason it relaxes blood vessels is that pericytes let go. If so then it could be used in hyperacute therapy to open the capillaries that have been closed down by clamping pericytes. Have your researcher get back to you with the answer.
http://www.medpagetoday.com/Cardiology/CHF/36635
The mortality reduction seen in acute heart failure with the novel
blood vessel relaxer serelaxin may be a real effect from reduced
end-organ damage and faster decongestion, exploratory analysis of the
RELAX-AHF trial data suggested.
Safety results from that trial
indicated a 37% reduction at 6 months in both cardiovascular death risk
and in all-cause mortality with numbers needed to treat of less than
30.
The effect was virtually identical in combined analysis of the phase
II and phase III studies with the drug (hazard ratio 0.62 for all-cause
death, P=0.0076), Marco Metra, MD, of the University of Brescia, Italy, and colleagues reported online in the Journal of the American College of Cardiology.
Serelaxin treatment was associated with reduced markers of cardiac,
renal, and liver damage and with less congestion at day two of the heart
failure admission, which all correlated with 6-month mortality
"providing a potential mechanism for the improved survival of
serelaxin-treated patients."
The rest at the link
No comments:
Post a Comment